© 2021 by Elsevier GmbH
Bitte nutzen Sie das untenstehende Formular um uns Kritik, Fragen oder Anregungen zukommen zu lassen.
Willkommen
Mehr InformationenB9783437223655.10001-8
10.1016/B9783437223655.10001-8
9783437223655
###
Surfactanttherapie des Atemnotsyndroms Frühgeborener (RDS) (S2k)
22.1
Definition
22.2
Pathophysiologie
22.3
Diagnostik
22.4
Therapie
22.4.1
Zeitpunkt der Therapie mit Surfactant
-
●
Prophylaktische oder frühe Behandlung (ab Geburt bis zu 60 Minuten postnatal)
-
●
Interventionsbehandlung (Rescue-Behandlung) mehr als 1–2 Stunden postnatal bei klinischen und/oder radiologischen Zeichen des RDS)
22.4.2
Wahl des Surfactantpräparats
22.4.3
Dosierung von natürlichen Surfactantpräparaten
22.4.4
Applikationsmodus von Surfactant beim RDS
22.4.5
Frühe Surfactanttherapie in Kombination mit CPAP-Therapie
INSURE
LISA
22.4.6
Einschränkungen zu den Aussagen INSURE versus LISA
22.5
Beatmung nach Surfactant
22.6
Surfactant und perinatale Kortikosteroide
22.7
Unerwünschte Effekte der Surfactantbehandlung
22.8
Surfactantbehandlung als Teil der Perinatalmedizin und Ausblick
Verfahren zur Konsensbildung
Literatur
1.
1.Ablow RC, Gross I, Effmann EL et al. (1977) The radiographic features of early onset Group B streptococcal neonatal sepsis. Radiology 124:771-777
2.
2.Ali E, Abdel Wahed M, Alsalami Z et al. (2016) New modalities to deliver surfactant in premature infants: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 29:3519-3524
3.
3.Ardell S, Pfister RH, Soll R (2015) Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 8:CD000144
4.
4.Baroutis G, Kaleyias J, Liarou T et al. (2003) Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 162:476-480
5.
5.Blennow M, Bohlin K (2015) Surfactant and noninvasive ventilation. Neonatology 107:330-336
6.
6.Couchard M, Polge J, Bomsel F (1974) [Hyaline membrane disease: diagnosis, radiologic surveillance, treatment and complications]. Ann Radiol (Paris) 17:669-683
7.
7.Dani C, Corsini I, Bertini G et al. (2011) Effect of multiple INSURE procedures in extremely preterm infants. J Matern Fetal Neonatal Med 24:1427-1431
8.
8.Fischer HS, Bührer C (2013) Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. Pediatrics 132:e1351-1360
9.
9.Giedion A, Haefliger H, Dangel P (1973) Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatric Radiol 1:145-152
10.
10.Gonzalez Garay AG, Reveiz L, Velasco Hidalgo L et al. (2014) Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome. Cochrane Database Syst Rev 10:Cd009708
11.
11.Göpel W, Kribs A, Härtel C et al. (2015) Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Acta Paediatr 104:241-246
12.
12.Göpel W, Kribs A, Ziegler A et al. (2011) Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 378:1627-1634
13.
13.Gortner L, Pohlandt F, Bartmann P et al. (1994) High-dose versus low-dose bovine surfactant treatment in very premature infants. Acta Paediatr 83:135-141
14.
14.Gortner L, Wauer RR, Hammer H et al. (1998) Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: a multicenter controlled clinical trial. Pediatrics 102:1153-1160
15.
15.Halliday HL, Tarnow-Mordi WO, Corcoran JD et al. (1993) Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 69:276-280
16.
16.Hascoet JM, Picaud JC, Ligi I et al. (2016) Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial. JAMA Pediatr 170:365-372
17.
17.Hentschel R, Brune T, Franke N et al. (2002) Sequential changes in compliance and resistance after bolus administration or slow infusion of surfactant in preterm infants. Intensive Care Med 28:622-628
18.
18.Herting E (2013) Less invasive surfactant administration (LISA) - ways to deliver surfactant in spontaneously breathing infants. Early Hum Dev 89:875-880
19.
19.Hutten MC, Kuypers E, Ophelders DR et al. (2015) Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation. Pediatr Res 78:664-669
20.
20.Isayama T, Iwami H, Mcdonald S et al. (2016) Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. JAMA 316:611-624
21.
21.Jobe A (1983) Respiratory distress syndrome--new therapeutic approaches to a complex pathophysiology. Adv Pediatr 30:93-130
22.
22.Jobe AH, Mitchell BR, Gunkel JH (1993) Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 168:508-513
23.
23.Joshi S, Kotecha S (2007) Lung growth and development. Early Hum Dev 83:789-794
24.
24.Kanmaz HG, Erdeve Ö, Canpolat FE et al. (2013) Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 131:e502-509
25.
25.Kari MA, Hallman M, Eronen M et al. (1994) Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics 93:730-736
26.
26.Kribs A, Roll C, Göpel W et al. (2015) Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr 169:723-730
27.
27.Kribs A, Vierzig A, Hünseler C et al. (2008) Early surfactant in spontaneously breathing with nCPAP in ELBW infants--a single centre four year experience. Acta Paediatr 97:293-298
28.
28.Morley CJ, Davis PG, Doyle LW et al. (2008) Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 358:700-708
29.
29.Pfister RH, Soll R, Wiswell TE (2009) Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev:CD006180
30.
30.Pillow JJ, Minocchieri S (2012) Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology 101:337-344
31.
31.Polin RA, Carlo WA (2014) Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics 133:156-163
32.
32.Proquitté H, Dushe T, Hammer H et al. (2007) Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. Respir Med 101:169-176
33.
33.Raimondi F, Migliaro F, Sodano A et al. (2014) Use of neonatal chest ultrasound to predict noninvasive ventilation failure. Pediatrics 134:e1089-1094
34.
34.Ramanathan R, Rasmussen MR, Gerstmann DR et al. (2004) A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 21:109-119
35.
35.Rey M, Segerer H, Kiessling C et al. (1994) Surfactant bolus instillation: effects of different doses on blood pressure and cerebral blood flow velocities. Biol Neonate 66:16-21
36.
36.Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev:Cd004454
37.
37.Rojas-Reyes MX, Morley CJ, Soll R (2012) Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 3:Cd000510
38.
38.Schmölzer GM, Kamlin CO, Dawson JA et al. (2011) Tidal volume delivery during surfactant administration in the delivery room. Intensive Care Med 37:1833-1839
39.
39.Seger N, Soll R (2009) Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev:CD007836
40.
40.Segerer H, Van Gelder W, Angenent FW et al. (1993) Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique. Pediatr Res 34:490-494
41.
41.Smith LJ, Mckay KO, Van Asperen PP et al. (2010) Normal development of the lung and premature birth. Paediatr Respir Rev 11:135-142
42.
42.Soll R, Özek E (2009) Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev:Cd000141
43.
43.Speer CP, Robertson B, Curstedt T et al. (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89:13-20
44.
44.Stevens TP, Harrington EW, Blennow M et al. (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev:CD003063
45.
45.Stichtenoth G, Walter G, Lange R et al. (2014) Surface tension of airway aspirates withdrawn during neonatal resuscitation reflects lung maturity. Pediatr Pulmonol 49:751-756
46.
46.Sweet DG, Carnielli V, Greisen G et al. (2016) European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology 111:107-125
47.
47.Sweet DG, Turner M, Stranak Z et al. (2015) A first-in-human clinical study on the safety and efficacy of a new synthetic surfactant (CHF5633) in preterm infants with respiratory distress syndrome. In: In: Selected Abstracts of the 1st Congress of joint European Neonatal Societies (jENS 2015). J Pediatr Neonat Individual Med, Budapest (Hungary), p e040213
48.
48.Thome UH, Carlo WA, Pohlandt F (2005) Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch Dis Child Fetal Neonatal Ed 90:F466-473
49.
49.Toti P, Buonocore G, Rinaldi G et al. (1996) Pulmonary pathology in surfactant-treated preterm infants with respiratory distress syndrome: an autopsy study. Biol Neonate 70:21-28
50.
50.Valls-I-Soler A, Lopez-Heredia J, Fernandez-Ruanova MB et al. (1997) A simplified surfactant dosing procedure in respiratory distress syndrome: the "side-hole" randomized study. Spanish Surfactant Collaborative Group. Acta Paediatr 86:747-751
51.
51.Van Kaam AH, De Jaegere AP, Borensztajn D et al. (2011) Surfactant replacement therapy in preterm infants: a European survey. Neonatology 100:71-77
52.
52.Yeh TF, Chen CM, Wu SY et al. (2016) Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 193:86-95
53.
53.Zhang L, Cao HY, Zhao S et al. (2015) Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials. Pulm Pharmacol Ther 34:46-54
54.
54.Zola EM, Gunkel JH, Chan RK et al. (1993) Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 122:453-459